First Financial Bankshares Inc Grows Position in Pfizer Inc. $PFE

Key Points

• First Financial Bankshares Inc increased its stake in Pfizer Inc. by 4.7%, acquiring an additional 18,696 shares, bringing its total holdings to 416,170 shares valued at approximately $10.5 million.
• Wall Street analysts have mixed ratings on Pfizer, with two analysts giving a Strong Buy rating, while the average consensus rating is "Hold" with a target price of $28.12.
• Pfizer recently declared a quarterly dividend of $0.43 per share, which translates to an annualized yield of 7.0%, and has a dividend payout ratio of 91.49%.

First Financial Bankshares Inc raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 416,170 shares of the biopharmaceutical company's stock after buying an additional 18,696 shares during the period. First Financial Bankshares Inc's holdings in Pfizer were worth $10,546,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in PFE. Clarity Asset Management Inc. purchased a new stake in Pfizer during the fourth quarter valued at about $27,000. Gould Capital LLC boosted its stake in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the period. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer during the first quarter valued at approximately $27,000. North Capital Inc. purchased a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. Finally, Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on PFE shares. HSBC dropped their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Morgan Stanley increased their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Jefferies Financial Group increased their price objective on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Bank of America increased their price objective on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Trading Up 0.7%

Shares of PFE traded up $0.18 during mid-day trading on Tuesday, hitting $24.94. 44,247,211 shares of the company's stock traded hands, compared to its average volume of 40,145,636. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The firm has a market capitalization of $141.77 billion, a P/E ratio of 13.26, a PEG ratio of 0.88 and a beta of 0.55. The business's 50-day moving average price is $24.82 and its 200-day moving average price is $24.37.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.